AZD 3043

Drug Profile

AZD 3043

Alternative Names: AZD3043; TD 4756; THRX 918661

Latest Information Update: 03 Aug 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Theravance
  • Developer AstraZeneca
  • Class Anaesthetics; Esters; Hypnosedatives
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaesthesia

Most Recent Events

  • 28 Jul 2011 Discontinued - Phase-I for Anaesthesia in Sweden (IV)
  • 28 Jul 2011 Discontinued - Phase-I for Anaesthesia in United Kingdom (IV)
  • 17 Dec 2009 AstraZeneca completes a second phase I trial in Anaesthesia in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top